{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:22:05Z","timestamp":1765545725830,"version":"3.38.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T00:00:00Z","timestamp":1323993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00228-011-1180-7","type":"journal-article","created":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T09:13:37Z","timestamp":1323940417000},"page":"715-721","source":"Crossref","is-referenced-by-count":8,"title":["Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release\/indinavir and desvenlafaxine extended-release\/indinavir"],"prefix":"10.1007","volume":"68","author":[{"given":"Michael W.","family":"Jann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Spratlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Momary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Penzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"VanDenBerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,16]]},"reference":[{"key":"1180_CR1","first-page":"1073","volume":"57","author":"Center for Disease Control and Prevention","year":"2008","unstructured":"Center for Disease Control and Prevention (2008) HIV prevalence estimates\u2014United States, 2006. Morb Mortal Wkly Rep 57:1073\u20131076","journal-title":"Morb Mortal Wkly Rep"},{"key":"1180_CR2","unstructured":"Joint United Nations Programme on HIV\/AIDS (2009) AIDS epidemic update 2009. http:\/\/www.unaids.org\/en\/KnowledgeCentre\/HIVData\/EpiUpdate\/EpiUpdArchive\/2009\/default.aso . Accessed October 28, 2010"},{"key":"1180_CR3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ajhp\/57.4.376","volume":"57","author":"SR Penzak","year":"2000","unstructured":"Penzak SR, Reddy YS, Grimsley SR (2000) Depression in patients with HIV infection. Am J Health-System Pharm 57:376\u2013389","journal-title":"Am J Health-System Pharm"},{"key":"1180_CR4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11904-008-0025-1","volume":"25","author":"JG Rabkin","year":"2008","unstructured":"Rabkin JG (2008) HIV and depression: 2008 review and update. Current HIV\/AIS Rep 25:163\u2013171","journal-title":"Current HIV\/AIS Reports"},{"key":"1180_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","volume":"304","author":"MA Thompson","year":"2010","unstructured":"Thompson MA, Aberg JA, Cahn P, Montaner JS et al (2010) International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society\u2014USA panel. JAMA 304:321\u2013333","journal-title":"JAMA"},{"key":"1180_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","volume":"41","author":"SV Otton","year":"1996","unstructured":"Otton SV, Ball SE, Cheung SW, Inaba T, Rupdolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalyzed by CYP2D6. Br J Clin Pharmacol 41:149\u2013156","journal-title":"Br J Clin Pharmacol"},{"key":"1180_CR7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2125.1997.00591.x","volume":"43","author":"SE Ball","year":"1997","unstructured":"Ball SE, Ahert D, Scatina J, Kao J (1997) Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine metabolism; comparative studies with selected SSRIs and effect on human hepatic CYP3A4, CYP2C9, and CYP1A2. Br J Clin Pharmacol 43:619\u2013626","journal-title":"Br J Clin Pharmacol"},{"key":"1180_CR8","first-page":"1","volume":"42","author":"A Oganesian","year":"2009","unstructured":"Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L (2009) Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharm Bull 42:1\u201317","journal-title":"Psychopharm Bull"},{"key":"1180_CR9","first-page":"62","volume":"35","author":"GL Levin","year":"2001","unstructured":"Levin GL, Nelson LA, DeVane CL, Preston SL, Eisle G, Carson SW (2001) A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharm Bull 35:62\u201371","journal-title":"Psychopharm Bull"},{"key":"1180_CR10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","volume":"101","author":"RB Kim","year":"1998","unstructured":"Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden DM, Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289\u2013294","journal-title":"J Clin Invest"},{"key":"1180_CR11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0022-3565(24)35293-0","volume":"292","author":"JH Hochman","year":"2000","unstructured":"Hochman JH, Chiba M, Yamazaki M, Lin JH (2000) Influence of P-glycoprotein on the transport and metabolism on indinavir in caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 292:292\u2013318","journal-title":"J Pharmacol Exp Ther"},{"key":"1180_CR12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0006-3223(96)00406-4","volume":"41","author":"LL Moltke Von","year":"1997","unstructured":"Von Moltke LL, Duan SX, Greenblatt DJ, Fogelman SM, Schmider J, Harmatz JS, Shader RI (1997) Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol Psychiatry 41:377\u2013380","journal-title":"Biol Psychiatry"},{"key":"1180_CR13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euroneuro.2010.04.004","volume":"20","author":"L Karlsson","year":"2010","unstructured":"Karlsson L, Schmitt U, Josefsson M, Carlson B, Ahlner J, Bengtsson F, Kugelberg FC, Hiemke C (2010) Blood\u2013brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 20:632\u2013640","journal-title":"Eur Neuropsychopharmacol"},{"key":"1180_CR14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/bdd.753","volume":"32","author":"CJ Bachman","year":"2011","unstructured":"Bachman CJ, Beauleiu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM (2011) Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Disposition 32:233\u2013234","journal-title":"Biopharm Drug Disposition"},{"key":"1180_CR15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/00912709922012006","volume":"39","author":"DK Yu","year":"1999","unstructured":"Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203\u20131211","journal-title":"J Clin Pharmacol"},{"key":"1180_CR16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/00498250701867889","volume":"38","author":"SF Zhou","year":"2008","unstructured":"Zhou SF (2008) Structure, function, and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:802\u2013812","journal-title":"Xenobiotica"},{"key":"1180_CR17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","volume":"323","author":"SG Aller","year":"2009","unstructured":"Aller SG, Yu J, Ward A, Weng Y et al (2009) Structure of P-glycoprotein reveals a molecular basis of poly-specific drug binding. Science 323:1718\u20131722","journal-title":"Science"},{"key":"1180_CR18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/clpt.1986.85","volume":"39","author":"PD Stolley","year":"1986","unstructured":"Stolley PD, Strom BL (1986) Sample size calculation for clinical pharmacology studies. Clin Pharmacol Ther 39:489\u2013490","journal-title":"Clin Pharmacol Ther"},{"key":"1180_CR19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/009127002401382650","volume":"42","author":"SR Penzak","year":"2002","unstructured":"Penzak SR, Acosta EP, Truner M, Edwards DJ, Hon YY, Desai HD, Jann MW (2002) Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmcol 42:1165\u20131170","journal-title":"J Clin Pharmcol"},{"key":"1180_CR20","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1023\/A:1018880726035","volume":"16","author":"PL Carver","year":"1999","unstructured":"Carver PL, Fleisher D, Zhou SY, Kaul D, Kazanjian P, Li C (1999) Meal composition effects of the oral bioavailability of indinavir in HIV-infectd patients. Pharm Res 16:718\u2013724","journal-title":"Pharm Res"},{"key":"1180_CR21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/00912700122010140","volume":"41","author":"MJ Shelton","year":"2001","unstructured":"Shelton MJ, Wynn HE, Hewitt RG, DiFrancesco R (2001) Effects of grapefruit juice in pharmacokinetic exposure to indinavir in HIV-positive patients. J Clin Pharmacol 41:435\u2013442","journal-title":"J Clin Pharmacol"},{"key":"1180_CR22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1345\/aph.1K563","volume":"42","author":"MA Sopko","year":"2008","unstructured":"Sopko MA, Ehret MJ, Grgas M (2008) Desvenlafaxine: another \u201cme too\u201d drug? Ann Pharmacotherapy 42:1439\u20131446","journal-title":"Ann Pharmacotherapy"},{"key":"1180_CR23","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.clinthera.2010.11.002","volume":"32","author":"JH Filho","year":"2010","unstructured":"Filho JH, Bonifacio FN, Bedor DCG et al (2010) Relative bioavailability of two formulations of venlafaxine extended-release 75\u00a0mg capsules in healthy Brazilian male volunteers: a single-dose, randomized sequence, open-label, two-period crossover study in fasting and fed states. Clin Ther 32:2088\u20132096","journal-title":"Clin Ther"},{"key":"1180_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","volume":"40","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption. Clin Pharmacokinet 40:159\u2013168","journal-title":"Clin Pharmacokinet"},{"key":"1180_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1385\/1-59259-924-9:041","volume-title":"Drug interactions in infectious disease","author":"SR Penzak","year":"2005","unstructured":"Penzak SR (2005) Mechanism of drug interactions 2: transport proteins. In: Piscitelli SC, Rodvold KA (eds) Drug interactions in infectious disease, 2nd edn. Humana, Totowa, NJ, pp 41\u201382","edition":"2"},{"key":"1180_CR26","first-page":"1","volume":"10","author":"M Saradhi","year":"2006","unstructured":"Saradhi M, Kumar N, Reddy RC, Tyagi RK (2006) Pregane and xenobiotic receptor (PXR): a promiscuous xenosensor in human health and disease. J Endocrinol Reproduct 10:1\u201312","journal-title":"J Endocrinol Reproduct"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1180-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-011-1180-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1180-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T21:45:39Z","timestamp":1742075139000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1180-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,16]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1180-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2011,12,16]]}}}